Should Biological Therapies Be Used During Pregnancy by Inflammatory Bowel Disease Patients?

Should Biological Therapies Be Used During Pregnancy by Inflammatory Bowel Disease Patients?
A new article sheds light on whether pregnant women with inflammatory bowel disease (IBD) should continue using anti-tumor necrosis factor (TNF) therapy. These therapies include the biological agents infliximab, adalimumab, certolizumab pegol, and golimumab, all of which block the naturally-occurring inflammatory molecule TNF. Overall, the study authors suggest discontinuing these treatments during the third trimester of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *